Phase II Randomized Study of Avelumab and Cetuximab Rechallenge in Pre-treated RAS/BRAF Wild-Type Metastatic Colorectal Cancer
- Trial ID
- 2024-519481-44-00
- Protocol
- CAVE-2
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this phase II randomized clinical study is to evaluate the **efficacy** in terms of Overall Survival (OS) of the combination of avelumab and cetuximab compared to cetuximab alone in patients with pre-treated RAS/BRAF wild type metastatic colorectal cancer. This objective is clinically relevant as it aims to determine whether the addition of avelumab to cetuximab can improve survival outcomes in this patient population, potentially offering a more effective treatment strategy.
Secondary objectives include:
- To demonstrate superiority with regard to the Objective Response Rate (ORR) of avelumab and cetuximab combined compared to cetuximab alone.
- To demonstrate superiority with regard to Progression Free Survival (PFS) of the combination therapy compared to cetuximab alone.
- To determine the safety and tolerability of avelumab and cetuximab combined compared to cetuximab alone.
These secondary objectives are crucial for assessing the overall benefit-risk profile of the combination therapy, providing insights into its potential as a viable treatment option for metastatic colorectal cancer.
Participants
The clinical trial involves participants diagnosed with **colorectal metastatic cancer**. The study population includes both male and female subjects aged 18 years and older. Participants are required to have a histologically confirmed diagnosis of colorectal adenocarcinoma with metastatic disease. The trial does not include a vulnerable population. The selection criteria ensure that participants have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1, an estimated life expectancy of more than 12 weeks, and adequate hematological, hepatic, and renal function. Additionally, participants must have received prior treatment, including a first-line therapy containing an anti-EGFR drug with a major response, and a second-line therapy. The trial population was selected based on these criteria, but the total number of participants is not provided by the sponsor. Lifestyle considerations such as effective contraception are required for both male and female subjects throughout the study. The trial aims to evaluate the efficacy of avelumab and cetuximab combined in pre-treated RAS, BRAF wild-type metastatic colorectal cancer patients compared to cetuximab alone.
Plans and Procedures
The clinical trial is a **randomized**, **controlled**, phase II study designed to evaluate the efficacy of a combination therapy involving **avelumab** and **cetuximab** in patients with pre-treated RAS/BRAF wild-type **metastatic colorectal cancer**. The primary objective is to assess overall survival (OS) compared to cetuximab alone. The trial is expected to span approximately four years, with an estimated recruitment start date of July 21, 2022, and an anticipated end date of July 21, 2026. Participants will be randomly assigned to receive either the combination therapy or cetuximab alone, with both treatments administered via **IV infusion**.
Study visits are structured to ensure comprehensive monitoring and data collection. The initial inclusion visit, or screening, will confirm eligibility based on criteria such as adequate hematological, hepatic, and renal function, as well as a histologically proven diagnosis of colorectal adenocarcinoma. Participants must have an ECOG performance status of 0 to 1 and an estimated life expectancy of more than 12 weeks. Follow-up visits will occur regularly to assess treatment efficacy and safety, with endpoints including overall response rate (ORR), progression-free survival (PFS), and safety evaluations using the NCI-CTCAE version 5.0. The end-of-study visit will conclude the participant's involvement, summarizing the treatment outcomes and any adverse events experienced.
Participant involvement is expected to last up to 12 months, corresponding to the maximum treatment period. Conditions that may lead to early termination from the study include significant adverse events, disease progression, or withdrawal of consent. Effective contraception is required for all participants throughout the study and for at least two months after the last treatment administration to mitigate any potential risks to a developing fetus. The trial's design ensures rigorous assessment of both efficacy and safety, contributing valuable data to the understanding of treatment strategies for metastatic colorectal cancer.
Treatment
The clinical trial involves the administration of **CETUXIMAB**, a monoclonal antibody, as part of the experimental treatment regimen. **CETUXIMAB** is provided in the form of a **solution for infusion** and is administered via **intravenous (IV) infusion**. The dosing regimen for **CETUXIMAB** involves a maximum daily dose of 400 mg/m², with a total maximum dose not exceeding 13,000 mg/m² over the course of the treatment. The treatment period is set for a maximum of 12 months. The product has undergone re-packaging and labeling specifically for the clinical trial. Participant compliance with the dosing schedule will be monitored throughout the study.
**AVELUMAB** is also utilized in this clinical trial as part of the experimental treatment. It is a human monoclonal IgG1 antibody, provided as a **concentrate for solution for infusion**. Similar to **CETUXIMAB**, **AVELUMAB** is administered via **IV infusion**. The dosing schedule for **AVELUMAB** allows for a maximum daily dose of 800 mg/mL, with a total maximum dose of 20,000 mg/mL over the treatment period, which is also capped at 12 months. The product has been re-packaged and labeled for the purposes of the clinical trial. Compliance with the administration schedule will be closely monitored to ensure adherence to the protocol.
In this study, the combination of **AVELUMAB** and **CETUXIMAB** is being evaluated as a rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients. The primary objective is to assess the efficacy of this combination in terms of overall survival compared to **CETUXIMAB** alone. No additional non-experimental treatments, such as standard-of-care therapy or placebo, are specified in the trial protocol. The study is designed to ensure rigorous monitoring of participant compliance with the treatment regimen to maintain the integrity of the trial data.
Efficacy
The efficacy of the clinical trial will be assessed primarily through the measurement of **Overall Survival (OS)**. This is defined as the interval from enrollment to death from any cause. Secondary efficacy endpoints include the overall response rate (ORR) and progression-free survival (PFS), both evaluated according to RECIST 1.1 criteria. ORR is defined as the proportion of patients who achieve a partial or complete response to therapy, while PFS is the time from random assignment in the clinical trial to disease progression or death from any cause.
Safety endpoints will also be evaluated, including adverse events (AEs) assessed throughout the trial using the NCI-CTCAE version 5.0, along with clinical laboratory assessments, vital signs, and electrocardiogram (ECG) parameters. The trial involves the administration of avelumab and cetuximab, with the efficacy of this combination being compared to cetuximab alone in pre-treated RAS, BRAF wild-type metastatic colorectal cancer patients. The trial is designed to provide comprehensive data on the efficacy and safety of the treatment regimen over the course of the study period.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Signed written informed consent before any trial-related procedure is undertaken that is not part of the standard patient management
- Male or female subjects aged ≥ 18 years.
- Histologically proven diagnosis of colorectal adenocarcinoma.
- Diagnosis of metastatic disease.
- RAS (NRAS and KRAS exon 2,3 and 4) and BRAF wild-type in liquid biopsy at initial diagnosis (according to NGS, Foundation/Roche).
- Efficacy of a first line therapy containing anti-EGFR drug with a major response achieved (i.e. complete or partial response according to RECIST criteria v1.1).
- Received a second line therapy.
- More than 4 months since the last dose of anti-EGFR drug administered in first line treatment before randomization.
- Measurable disease according to RECIST criteria v1.1.
- ECOG PS of 0 to 1 at trial entry.
- Estimated life expectancy of more than 12 weeks.
- Adequate hematological function defined by white blood cell (WBC) count ≥ 2.5 × 109 /L with absolute neutrophil count (ANC) ≥ 1.5 × 109 /L, lymphocyte count ≥ 0.5 × 109 /L, platelet count ≥ 100 × 109 /L, and hemoglobin ≥ 9 g/dL (may have been transfused).
- Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range and AST and alanine aminotransferase (ALT) levels ≤ 2.5 × ULN for all subjects or AST and ALT levels ≤ 5 x ULN (for subjects with documented metastatic disease to the liver).
- Adequate renal function defined by an estimated creatinine clearance > 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method).
- Effective contraception for both male and female subjects throughout the study and for at least 2 months after last study treatment administration if the risk of conception exists (Note: The effects of the trial drug on the developing human fetus are unknown; thus, women of childbearing potential and men must agree to use effective contraception, defined as 2 barrier methods, or 1 barrier method with a spermicide, an intrauterine device, or use of oral female contraceptive. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this trial, the treating physician should be informed immediately).
Exclusion Criteria
- Any contraindication to cetuximab and/or avelumab
- Past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix.
- Pregnancy.
- Breastfeeding.
- Participation in a clinical study or experimental drug treatment within 30 days before enrollment
- Subjects receiving immunosuppressive agents (such as steroids) for any reason, should be tapered off these drugs before initiation of the trial treatment, with the exception of: - Subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement dose, equivalent to ≤ 10 mg prednisone daily - Intranasal, inhaled, topical steroids, - Local steroid injection (e.g., intra-articular injection) - Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent - Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
- All subjects with brain metastases, except those meeting the following criteria: - Brain metastases have been treated locally - No ongoing neurological symptoms related to the brain localization of the disease (sequelae that are a consequence of the treatment of the brain metastases are acceptable)
- Prior organ transplantation, including allogeneic stem-cell transplantation
- Significant acute or chronic infections including, among others: - Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome - Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive)
- Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent: - Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible. - Subjects requiring hormone replacement with corticosteroids are eligible if steroids are administered only for the purpose of hormonal replacement and at doses ≤ 10 mg or equivalent prednisone per day. - Administration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable. - Active infection requiring systemic therapy.
- . Previous or ongoing administration of systemic steroids for the management of an acute allergic phenomenon is acceptable as long as it is anticipated that the administration of steroids will be completed in 14 days, or that the daily dose after 14 days will be ≤ 10 mg per day of equivalent prednisone.
- Known severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v 5 Grade ≥ 3), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma).
- History of hypersensitivity to Polysorbate 80 that led to unacceptable toxicity requiring treatment cessation
- Persisting toxicity related to prior therapy of Grade > 1 NCI- CTCAE v 5.0.
- Known alcohol or drug abuse.
- . Clinically significant (that is active) cardiovascular disease: cerebral vascular accident/stroke (<6 months prior to enrollment), myocardial infarction (<6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥ II), or serious uncontrolled cardiac arrhythmia requiring medication.
- History of keratitis, ulcerative keratitis or severe dry eye. Since contact lent use is also a risk factor for keratitis and ulceration, it is not recommended
- Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- Vaccination within 4 weeks of the first dose of avelumab and cetuximab and while on treatment is prohibited except for administration of inactivated vaccine (i.e. inactivated influenza vaccine).
- Legal incapacity or limited legal capacity.
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Italy | Recruiting | 21 Jul 2022 | 173 |
Sites & Investigators
Research sites
Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
CETUXIMAB | Test | — | IV INFUSION | 400 | 12 | SUB01178MIG |
AVELUMAB | Test | — | IV INFUSION | 800 | 12 | SUB180078 |

